All In Biotech

Drug Trial Radar · NCT06548815

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

A Single-center, Single-administration, Randomized, Placebo-controlled, Dose-escalation Trial Evaluated the Safety, Tolerability, PK, and PD Parameters of GZR4 in Healthy Male Adult Subjects

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Aug 29, 2022

Primary completion

Mar 24, 2023

Study completion Mar 24, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.

Conditions

  • Diabetes

Interventions

  • GZR4Drug

    Ascending single doses - 4 dose levels.

  • PlaceboDrug

    Ascending single doses - 4 dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAETime frame: Baseline to Day29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals Co., Ltd

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.